國邦醫藥(605507.SH):子公司鹽酸多西環素獲得獸藥產品批准文號批件
格隆匯11月25日丨國邦醫藥(605507.SH)公佈,近日,國邦醫藥全資子公司山東國邦藥業有限公司(“山東國邦”)收到農業農村部審批簽發的“鹽酸多西環素”的獸藥產品批准文號批件。
鹽酸多西環素是一種四環素類廣譜抗生素,具有廣譜抑菌作用,用於革蘭氏陽性菌、陰性菌和支原體等引起的感染。
山東國邦已取得上述產品的《獸藥生產許可證》及《獸藥GMP證書》,同時上報國家農業農村部相關資料,目前已取得該產品的批准文號批件,具備上市銷售條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.